SHR-1703

Unknown / undisclosed

Phase 2/3underway

Evidence outlook · registrational

Eosinophilic Granulomatosis with Polyangiitis: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-12.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
NCT06653322 · Guangdong Hengrui Pharmaceutical Co., Ltd
2024-11-21 – 2027-12 · Asthma With Eosinophilic Phenotype
What this study did
Phase 2/3 (1)
Eosinophilic Granulomatosis with Polyangiitis
NCT05979051 · Guangdong Hengrui Pharmaceutical Co., Ltd
2023-11-16 – 2028-12 · Eosinophilic Granulomatosis With Polyangiitis
What this study did
Phase 2 (2)
Other / comorbidity
NCT06441812 · Guangdong Hengrui Pharmaceutical Co., Ltd
2024-07-19 – 2028-09 · Eosinophilic Asthma Patients
What this study did
NCT05522439 · Jiangsu HengRui Medicine Co., Ltd.
2022-12-22 – 2024-09-12 · Asthma With Eosinophilic Phenotype
What this study did
Phase 1 (4)
Other / comorbidity
NCT07701239 · Guangdong Hengrui Pharmaceutical Co., Ltd
2026-07 – 2027-04 · Asthma With Eosinophilic Phenotype
What this study did
NCT05042401 · Jiangsu HengRui Medicine Co., Ltd.
2021-10-12 – 2023-06-15 · Asthma
What this study did
NCT04855591 · Atridia Pty Ltd.
2021-06-14 – 2021-11-18 · Asthma
What this study did
NCT04480762 · Jiangsu HengRui Medicine Co., Ltd.
2020-08-04 – 2021-09-21 · Asthma
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 2 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SHR-1703: this drugPhase 2/3UndisclosedIL-5not yet gradedNo reviewed efficacy summary
Depemokimab
Approved(overall)
Monoclonal antibodyIL-5Reliable signal
NCT05274750: Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read) (Baseline (Day 1) and at Week 52): Depemokimab -0.6 Scores on a Scale (Standard Error 0.14) vs Placebo 0.2 Scores on a Scale (Standard Error 0.15)
NCT05281523: Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read) (Baseline (Day 1) and at Week 52): Depemokimab -0.5 Scores on scale (Standard Error 0.14) vs Placebo 0.1 Scores on scale (Standard Error 0.15)
Mepolizumab (Nucala)
Approved(overall)
Monoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingReliable signal
NCT04133909: Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Mepolizumab 100 mg 0.8 Exacerbations per year (95% CI 0.7 to 0.91) | Placebo 1.01 Exacerbations per year (95% CI 0.89 to 1.15)
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
BAT2606
Phase 1(overall)
Monoclonal antibodyIL-5Partial signal
NCT05576454: In 207 subjects enrolled and randomized, the 90% confidence intervals of the geometric mean ratios of maximum concentration and area under the curve from time 0 to infinity were within 80.00%-125.00%.

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SHR-1703 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Phase 1Asthma With Eosinophilic PhenotypeNot yet recruiting
Est. primary completion 2027-04 · NCT07701239 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Asthma With Eosinophilic PhenotypeActive not recruiting
Est. primary completion 2027-09 · NCT06653322 · CT.gov ↗
What to watch
2028 (2)
September 2028 (1)
Phase 2Eosinophilic Asthma PatientsRecruiting
Est. primary completion 2028-09 · NCT06441812 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2/3Eosinophilic Granulomatosis with PolyangiitisRecruiting
Est. primary completion 2028-12 · NCT05979051 · CT.gov ↗
What to watch

See the full readout calendar ↗